156 related articles for article (PubMed ID: 23565554)
1. Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.
Grözinger G; Plentz R; Horger M
J Gastroenterol Hepatol; 2013 Mar; 28(3):588. PubMed ID: 23565554
[No Abstract] [Full Text] [Related]
2. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
[TBL] [Abstract][Full Text] [Related]
3. Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.
Lulla PD; Brammer JE; Bandeali S; Lynch GR
J Gastrointest Cancer; 2013 Mar; 44(1):98-101. PubMed ID: 23054578
[No Abstract] [Full Text] [Related]
4. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
[No Abstract] [Full Text] [Related]
5. Long-term treatment of hepatocellular carcinoma with sorafenib.
Rombolà F; Spinoso A
Infez Med; 2013 Jun; 21(2):167-8. PubMed ID: 23774984
[No Abstract] [Full Text] [Related]
6. Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
Shin SK; Jung YK; Yoon HH; Kwon OS; Kim YS; Choi DJ; Kim JH
Korean J Gastroenterol; 2014 Jan; 63(1):47-50. PubMed ID: 24463289
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
Nakamura Y; Kawaoka T; Higaki T; Fukumoto W; Honda Y; Iida M; Fujioka C; Kiguchi M; Aikata H; Chayama K; Awai K
Eur J Radiol; 2018 Jan; 98():41-49. PubMed ID: 29279169
[TBL] [Abstract][Full Text] [Related]
8. Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Berasain C
Gut; 2013 Dec; 62(12):1674-5. PubMed ID: 23481262
[No Abstract] [Full Text] [Related]
9. Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
Azmi AN; Chan WK; Goh KL
J Dig Dis; 2015 Sep; 16(9):537-40. PubMed ID: 26147446
[No Abstract] [Full Text] [Related]
10. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
[No Abstract] [Full Text] [Related]
11. Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
Chen X; Ma Z; Huang Y; He L; Liang C; Shi C; Zhang Z; Liang C; Liu Z
J Magn Reson Imaging; 2017 Jul; 46(1):248-256. PubMed ID: 27783444
[TBL] [Abstract][Full Text] [Related]
12. Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
Huang YH; Siao FY; Yen HH
Gastroenterology; 2015 Aug; 149(2):e12-3. PubMed ID: 26123559
[No Abstract] [Full Text] [Related]
13. Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib.
Choi JI; Imagawa DK; Bhosale P; Bhargava P; Tirkes T; Seery TE; Lall C
Clin Mol Hepatol; 2014 Jun; 20(2):218-22. PubMed ID: 25032190
[TBL] [Abstract][Full Text] [Related]
14. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
Tovoli F; Renzulli M; Negrini G; Brocchi S; Ferrarini A; Andreone A; Benevento F; Golfieri R; Morselli-Labate AM; Mastroroberto M; Badea RI; Piscaglia F
Eur Radiol; 2018 Sep; 28(9):3611-3620. PubMed ID: 29633000
[TBL] [Abstract][Full Text] [Related]
15. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
16. Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution.
Piscaglia F; Cucchetti A; Dietrich CF; Salvatore V
J Hepatol; 2013 Nov; 59(5):924-5. PubMed ID: 23928406
[No Abstract] [Full Text] [Related]
17. Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma.
Piscaglia F; Salvatore V; Venerandi L
Dig Liver Dis; 2013 May; 45(5):367-8. PubMed ID: 23562444
[No Abstract] [Full Text] [Related]
18. Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Tanoglu A; Karagoz E
Asian Pac J Cancer Prev; 2014; 15(2):1063. PubMed ID: 24568452
[No Abstract] [Full Text] [Related]
19. Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Elleuch N; Ennaifer R; Romdhane H; Cheikh M; Hefaiedh R; Bougassas W; Ben Nejma H; BelHadj N
Tunis Med; 2015 Jun; 93(6):350-2. PubMed ID: 26644095
[TBL] [Abstract][Full Text] [Related]
20. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
[Next] [New Search]
